Etiopathogenesis and biochemical and immunologic evaluation of spondyloarthropathies

Current Opinion in Rheumatology

Volumn 8, Issue 4, 1996, Pages 309-315

  Scofield, R Hal ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA;

CHLAMYDIACEAE; HLA SYSTEM; HUMAN; KLEBSIELLA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPONDYLOARTHROPATHY; YERSINIA;

EID: 0029757689     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199607000-00006     Document Type: Review

References (72)

1. Feltkamp B, Khan MA, López de Castro J: The pathogenic role of HLA-B27. Immunol Today 1996, 17:5-7.
2. Feltkamp B: HLA-B27 since 1990. Clin Rheumatol 1996, 15S:9.
3. Archer JR: Hypothesis: ankylosing spondylitis, Ig, and transforming growth factors. Ann Rheum Dis 1995, 54:544-546.
4. Hocini H, Isaki S, Benlahrache C, Vitalis L, Chevalier X, Larget-Piet B, Boutvet JP: Increased levels of serum IgA as IgA1 monomers in ankylosing spondylitis. Ann Rheum Dis 1992, 51:790-792.
5. Peeters AJ, Daha MR, Smeets TJ, Breedveld FC: Bone marrow IgA and IgA subclass synthesis In ankylosing spondylitis. J Rheumatol 1992, 19:751-753.
6. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J: Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992, 175:671-682.
7. van Vlasselaer P, Punnonen J, de Vries JE: Transforming growth factor-beta directs IgA switching in human B cells. J Immunol 1992, 148:2062-2067.
8. Centrella M, McCarthy TL, Canalis E: Transforming growth factor-beta and bone remodeling. J Bone Joint Surg Am 1991, 73:1418-1428.
9. Hermann E, Yu DTY, Meyer zum Büschenfelde K-H, Fleischer B: HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993, 342:646-650.
10. Diaz-Gallo C, Moscovitch-Lopatin M, Strom TB, Kelley VR: An anergic, islet-infiltrating T-cell clone that suppresses murine diabetes secretes a factor that blocks interleukin 2/interleukin 4-dependent proliferation. Proc Natl Acad Sci U S A 1992, 89:8656-8660.
11. Pankewycz OG, Guan JX, Benedict JF: A protective NOD islet-infiltrating CD8+ T cell clone, IS 2.15, has in vitro immunosuppressive properties. Eur J Immunol 1992, 22:2017-2023.
12. Stichtenoth DO, Wollenhaupt J, Andersone D, Zeidler H, Frölich JC: Elevated serum nitrate concentrations In active spondyloarthropathies. Br J Rheumatol 1995, 34:616-619.
13. Ialenti A, Moncada D, Di Rosa M: Modulation of adjuvant arthritis by endogenous nitric oxide. Br J Pharmacol 1993, 10:701-706.
14. Farrell AJ, Blake DR, Palmer RMJ, Moncada S: Increased concentration of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992, 51:1219-1222.
15. Kennedy LG, Will R, Cain A: Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol 1993, 20:1900-1904.
16. Machtey I: Sex ratio in spondyloarthropathy. J Rheumatol 1994, 21:1978-1979.
17. James WH: Sex ratio in ankylosing spondylitis. J Rheumatol 1995, 22:794-795.
18. James WH: The sex ratios of probands and of secondary cases in conditions of multifactorial inheritance where liability varies with sex. J Med Genet 1991, 28:41-43.
19. Järvinen P: Occurrence of ankylosing spondylitis in nationwide series of twins. Arthritis Rheum 1995, 38:381-383. This study is the first systematic estimate of the concordance rate among twins with ankylosing spondylitis. The 50% concordance among identical twins (compared with 15% to 20% among dizygotic twins) indicates that disease expression of ankylosing spondylitis is largely genetically controlled.
20. van der Linden SM, Valkenberg HA, de Jongh B, Cats A: The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984, 23:241-249.
21. Calin A, Marder A, Becks E, Burns T: Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls. Arthritis Rheum 1983, 26:1460-1464.
22. McDaniel DO, Acton RT, Barger BO, Koopman WJ, Reveille JD: Association of a 9.2-kilobase Pvull class I major histocompatibility complex restriction fragment length polymorphism with ankylosing spondylitis. Arthritis Rheum 1987, 30:894-900.
23. Ahearn JM Jr, Calomiris JJ, Wigley FM, Jabs DA, Bias WM, Hochberg MC: Characterization of the class I 9.2 kb Pvull restriction fragment length polymorphism (RFLP): linkage to HLA-A and lack of disease association. Arthritis Rheum 1989, 32:870-876.
24. Durand JP, Taurog JD: Association between AS and a 9.2 kb Pvull class I HLA DNA restriction fragment. J Rheumatol 1988, 15:1119-1122.
25. Reveille JD, Suarez-Almazor ME, Russell AS, Go RCP, Appleyard J, Barger BO, Acton RT, Koopman WJ, McDaniel DO: HLA in ankylosing spondylitis: is HLA-B27 the only MHC gene involved with disease pathogenesis? Semin Arthritis Rheum 1994, 23:295-309.
26. Robinson WP, van der Linden SM, Khan MA, Rentsch HU, Cats A, Russell A, Thomson G: HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum 1989, 32:1135-1141.
27. Rubin LA, Amos CI, Wade JA, Martin JR, Bale SJ, Little AH, Gladman DD, Banney GE, Rubenstein JD, Siminovitch KA: Investigating the genetic basis for ankylosing spondylitis: linkage studies with the major histocompatibility complex region. Arthritis Rheum 1994, 37:1212.
28. Maksymowych WP, Tao S, Li Y, Wing M, Russell AS: Allelic variation at the TAP 1 locus influences disease phenotype in HLA-B27 positive individuals with ankylosing spondylitis. Tissue Antigens 1995, 45:328-332. This study finds that an RFLP of TAP1, which lies within the major histocompatibility complex, is associated with peripheral arthritis in patients with ankylosing spondylitis.
29. Gladman DD, Farewell VT: The role of HLA antigens as indicators of disease progression in psoriatic arthritis: multivariate relative risk model. Arthritis Rheum 1995, 38:845-850.
30. Yamaguchi A, Tsuchiya N, Mitsui H, Shiota M, Ogawa A, Tokunaga K, Yoshinoya S, Juji T, Ito K: Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Arthritis Rheum 1995, 38:1672-1677. HLA-B27 and HLA-B39 share amino acid residues critical to formation of the B pocket of the peptide-binding groove. The data showing that HLA-B39 is found in B27-negative ankylosing spondylitis patients (Gladman et al., Arthritis Rheum 1995, 38:845-850) and data from this study showing that HLA-B39 affects the progression of psoriatic arthritis may indicate that the presence of these amino acids is important to the pathogenesis of spondyloarthropathy.
31. Saraux A, de Saint Pierre V, Baron D, Vais I, Koreichi A, Youinou P, Le Goff P: The antiperinuclear factor in spondyloarthropathies. Br J Rheumatol 1995, 34:812-914.
32. European Spondylarthropathy Study Group: Preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991, 34:1218-1227.
33. Neinhuis RFL, Mandema E: A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 1964, 23:302-305.
34. Youinou P, Le Goff P, Dumay A, Lefong A, Fauquert P, Jouquan J: The antiperinuclear factor. I: Clinical and serologic associations. Clin Exp Rheumatol 1990, 8:259-264.
35. Sondag-Tshroots IRJM, Aaij C, Smith JW, Feltkamp TEW: The antiperinuclear factor: I. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. Ann Rheum Dis 1979, 38:248-251.
36. Janssens X, Veys EM, Verbruggen G, Declercq L: The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol 1988, 15:1346-1350.
37. Meyer O, Tauxe F, Fabregas M, Gabay G, Goycochea M, Haim T, Elias A, Khan MF: Anti-RA33 antinuclear antibodies In rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratan and antiperinuclear antibodies. Clin Exp Rheumatol 1993, 11:473-478.
38. Koh W-H, Dunphy J, Dixey J, Calin A, McHugh NJ, Maddison PJ: Atypical antineutrophil cytoplasmic antibodies in patients with ankylosing spondylitis. Br J Rheumatol 1995, 34:695-696. Three ankylosing spondylitis patients are described who had atypical ANCA. Such a finding may be related to occult bowel inflammation. These interesting case reports will require follow-up with serologic studies of large numbers of patients.
39. Gross WI, Schmidt WH, Csernok E: Antineutrophil cytoplasmic autoantibody-associated diseases: a rheumatologist's perspective. Am J Kidney Dis 1991, 18:157-179.
40. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppala K: High frequency of silent inflammatory bowel disease in spondyloarthropathy. Arthritis Rheum 1994, 37:23-31.
41. Mielants H, Veys Em, Cuveilier C, De Vos M, Botelberghe L: HLA-B27 related arthritis and bowel inflammation: II. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol 1985, 12:294-298.
42. Biasi D, Carletto A, Caramaschi P, Bellavite P, Andrioli G, Caraffi M, Pacor ML, Bambara LM: Neutrophil functions, spondyloarthropathy and HLA-B27: a study of 43 patients. Clin Exp Rheum 1995, 13:623-627.
43. Leirisalo Repo MH, Tiilikainen Kosunen TU, Laitinen O: Chemotaxis in yersinia arthritis: HLA-B27 positive neutrophlls show high stimulated motility in vitro. Arthritis Rheum 1980, 23:1036-1044.
44. Pease CT, Fennel M, Breweton DA: Polymorphonuclear leucocyte motility in men with ankylosing spondylitis. Ann Rheum Dis 1989, 48:35-41.
45. Pease CT, Fordham JN, Currey HLF: Polymorphonuclear cell motility, ankylosing spondylitis, and HLA-B7. Ann Rheum Dis 1984, 43:279-284.
46. Koivuranta-Vaara P, Repo H, Leirisalo M, Kiistala L, Osterman T, Vapaatalo H: Enhanced neutrophil migration in vivo in HLA-B27 positive subjects. Ann Rheum Dis 1984, 43:181-185.
47. Gross WL, Lüdemann G, Ullmann U, Schmidt KL: Klebsiella induced LIF response in Klebsiella infection and ankylosing spondylitis. Br J Rheumatol 1983, 22(suppl 2):50-52.
48. Sheldon PJ, Pell PA: Lymphocyte proliferation responses to bacterial antigens in B27 associated arthropathies. Br J Rheumatol 1985, 24:11-18.
49. Hermann E, Sucké B, Droste U, Meyer zum Büschenfelde K-H: Klebsiella pneumoniae-reactive T cells in blood and synovial fluid of patients with ankylosing spondylitis. Comparison with HLA-27-positive healthy control subjects in a limiting dilution analysis and determination of the specificity of synovial fluid T cell clones. Arthritis Rheum 1995, 38:1277-1282. The authors found quantitatively fewer T cells reactive with Klebsiella in the peripheral blood of ankylosing spondylitis patients compared with controls. Like most good science this interesting study raises more questions than it answers. What is the mechanism for the reduced number of and-Klebsiella T cells in the blood of ankylosing spondylitis patients?
50. Hermann E, Grabe H, Mayat W-J, Meyer zum Büschenfelde K-H, Fliescher B: Lower frequency of Yersinia-reactive peripheral blood T cells in acute Yersinia-induced arthritis: Indication of a defective first line of defense. Clin Rheumatol 1992, 11:158.
51. Mäki-Ikola U, Nissilä M, Lehtinen K, Leirisalo-Repo M, Toivanen P, Granfors K: Antibodies to Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis in the sera of patients with axial and peripheral form of ankylosing spondylitis. Br J Rheumatol 1995, 34:413-417.
52. Mäki-Ikola O, Nissilä M, Lehtinen K, Leirisalo-Repo M, Granfors K: IgA1 and IgA2 subclass antibodies against Klebsiella pneumoniae in the sera of patients with peripheral and axial types of ankylosing spondylitis. Ann Rheum Dis 1995, 54:631-635.
53. Wordsworth BP, Hughes RA, Allan I, Keat AC, Bell JI: Chlamydial DNA is absent from the joints of patients with sexually acquired reactive arthritis. Br J Rheumatol 1990, 29:208-210.
54. Poole ES, Highton J, Wilkins RJ, Lamont IL: A search for chlamydia trachomatis in synovial fluid from patients with reactive arthritis using the polymerase chain reaction and antigen detection methods. Br J Rheumatol 1992, 31:31-34.
55. Taylor-Robinson D, Gilroy CB, Thomas BJ, Keat ACS: Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet 1992, 340:81-82.
56. Palmer HM, Gilroy CB, Thomas BJ, Hay PE, Gilchrist C, Taylor-Robinson D: Detection of Chlamydia trachomatis by the polymerase chain reaction in swabs and urine from men with non-gonococcal urethritis. Clin Pathol 1991, 44:321-325.
57. Rahman MU, Cheema MA, Schumacher HR Hudson AP: Molecular evidence for the presence of Chlamydia in the synovium of patients with Reiter's syndrome. Arthritis Rheum 1992, 35:521-529.
58. Bas S, Griffais R, Kvien TK, Glennås, Melby K, Vischer TL: Amplification of plasmid and chromosomal Chlamydia DNA in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies. Arthritis Rheum 1995, 38:1005-1013. By amplifying both plasmid and chromosomal DNA this study provides evidence that is consistent with intact (viable ?) organism being present in the synovial fluid of patients with spondyloarthropathies.
59. Gripenberg-Lerche C, Skurnik M, Zhang L, Söderström K-O, Toivanen P: Role of YadA in arthritogenicity of Yersinia enterocolitica serotype O:8 experimental studies with rats. Infect Immunol 1994, 62:5568-5575.
60. Gripenberg-Lerche C, Skurnik M, Toivanen P: Role of YadA-mediated collagen binding In arthritogenicity of Yersinia enterocolitica serotype O:8 studies with rats. Infect Immunol 1995, 63:3222-3226.
61. Schulze-Koops H, Burhardt H, Heesemann J, von der Mark K, Emmrich F: Characterization of the binding region for the Yersinia enterocolitica adhesin YadA in types I and II collagen. Arthritis Rheum 1995, 38:1283-1289.
62. Scofield RH, Warren WL, Koelsch G, Harley JB: A hypothesis for the immune dysregulation in spondyloarthropathy: contributions from enteric organisms, B27 structure, peptides bound by B27 and convergent evolution. Proc Natl Acad Sci U S A 1993, 90:9330-9334.
63. Scofield RH, Kurien B, Gross T, WL Warren, Harley JB: HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 1995, 345:1542-1544. A peptide from B27 is bound by B27 as are a series of peptides from bacteria that mimic the B27-derived peptide. The B27-derived and B27-bound peptide, as well as the bacterial peptides binding and mimicking B27, are the basis for a new theory of disease that combines the molecular mimicry and arthritogenic peptide hypotheses.
64. Davenport MP: The promiscuous B27 hypothesis. Lancet 1995, 346:500-501. Perhaps B27 binding itself is not critical to pathogenesis of spondyloarthropathy, but instead B27 peptide(s) bound and presented by HLA class II (and mimicked by bacteria ?) are critical. Such a peptide would need to be bound by many, if not all, HLA class II complexes in order to explain the lack of association of spondyloarthropathy with HLA class II.
65. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA, Strominger JL: Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992, 358:764-768.
66. Aiko S, Grisham MB: Spontaneous intestinal inflammation and nitric oxide production in HLA-B27 transgenic rats. Gastroenterology 1995, 105:142-150.
67. Hammer RE, Richardson JA, Simmons WA, White AL, Breban M, Taurog JD: High prevalence of colorectal cancer in HLA-B27 transgenic F344 rats with chronic inflammatory bowel disease. J Invest Med 1995, 43:262-267.
68. Nickerson CL, Hanson J, David CS: Expression of HLA-B27 in transgenic mice is dependent on the mouse H-2D genes. J Exp Med 1990, 172:1255-1261.
69. 2-microglobulin but only after removal from a pathogen-free environment.
70. Weinreich S, Eulderink F, Capkova J, Pla M, Gaede K, Heesmann J, van Alphen L, Zurcher C, Hoebe-Hewryk B, Kievits F, Ivnyi P: HLA-B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice. Hum Immunol 1995, 42:103-115.
71. Weinreich S, Hoebe B, Ivanyi P: Maternal age influences risk for HLA-B27 associated ankylosing enthesopathy in transgenic mice. Ann Rheum Dis 1995, 54:754-756.
72. Sayeeduddin S, Ishaq N, Rao URK: Birth order effect in rheumatoid arthritis. Br J Rheumatol 1994, 33:598-599.